191 related articles for article (PubMed ID: 2026621)
1. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
[TBL] [Abstract][Full Text] [Related]
2. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
[TBL] [Abstract][Full Text] [Related]
3. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
[TBL] [Abstract][Full Text] [Related]
4. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
Bos IG; Lubbers YT; Roem D; Abrahams JP; Hack CE; Eldering E
J Biol Chem; 2003 Aug; 278(32):29463-70. PubMed ID: 12773530
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate.
Patston PA; Gettins P; Beechem J; Schapira M
Biochemistry; 1991 Sep; 30(36):8876-82. PubMed ID: 1888745
[TBL] [Abstract][Full Text] [Related]
6. Secondary structure changes stabilize the reactive-centre cleaved form of SERPINs. A study by 1H nuclear magnetic resonance and Fourier transform infrared spectroscopy.
Perkins SJ; Smith KF; Nealis AS; Haris PI; Chapman D; Bauer CJ; Harrison RA
J Mol Biol; 1992 Dec; 228(4):1235-54. PubMed ID: 1335516
[TBL] [Abstract][Full Text] [Related]
7. A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule.
Aulak KS; Eldering E; Hack CE; Lubbers YP; Harrison RA; Mast A; Cicardi M; Davis AE
J Biol Chem; 1993 Aug; 268(24):18088-94. PubMed ID: 8349686
[TBL] [Abstract][Full Text] [Related]
8. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization.
Eldering E; Verpy E; Roem D; Meo T; Tosi M
J Biol Chem; 1995 Feb; 270(6):2579-87. PubMed ID: 7852321
[TBL] [Abstract][Full Text] [Related]
9. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
[TBL] [Abstract][Full Text] [Related]
10. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.
Verpy E; Couture-Tosi E; Eldering E; Lopez-Trascasa M; Späth P; Meo T; Tosi M
J Clin Invest; 1995 Jan; 95(1):350-9. PubMed ID: 7814636
[TBL] [Abstract][Full Text] [Related]
11. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
[TBL] [Abstract][Full Text] [Related]
12. C1-inhibitor-serine proteinase complexes and the biosynthesis of C1-inhibitor by Hep G2 and U 937 cells.
Patston PA; Medcalf RL; Kourteva Y; Schapira M
Blood; 1993 Dec; 82(11):3371-9. PubMed ID: 8241507
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional structure and molecular modelling of C1- inhibitor.
Perkins SJ
Behring Inst Mitt; 1993 Dec; (93):63-80. PubMed ID: 8172587
[TBL] [Abstract][Full Text] [Related]
14. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein.
Zahedi R; Bissler JJ; Davis AE; Andreadis C; Wisnieski JJ
J Clin Invest; 1995 Mar; 95(3):1299-305. PubMed ID: 7883978
[TBL] [Abstract][Full Text] [Related]
15. Hereditary and acquired deficiencies of C1 inhibitor.
Davis AE
Immunodefic Rev; 1989; 1(3):207-26. PubMed ID: 2698641
[TBL] [Abstract][Full Text] [Related]
16. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
17. Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.
Patston PA; Roodi N; Schifferli JA; Bischoff R; Courtney M; Schapira M
J Biol Chem; 1990 Jun; 265(18):10786-91. PubMed ID: 2191958
[TBL] [Abstract][Full Text] [Related]
18. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.
Perlmutter DH; Glover GI; Rivetna M; Schasteen CS; Fallon RJ
Proc Natl Acad Sci U S A; 1990 May; 87(10):3753-7. PubMed ID: 2160076
[TBL] [Abstract][Full Text] [Related]
19. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sulikowski T; Bauer BA; Patston PA
Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
[TBL] [Abstract][Full Text] [Related]
20. Understanding the specificity of serpin-protease complexes through interface analysis.
Rashid Q; Kapil C; Singh P; Kumari V; Jairajpuri MA
J Biomol Struct Dyn; 2015; 33(6):1352-62. PubMed ID: 25052369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
